Protein pushes breast cancer cells to metastasize

July 9, 2014

Using an innovative tool that captures heretofore hidden ways that cells are regulated, scientists at Rockefeller University have identified a protein that makes breast cancer cells more likely to metastasize.

What's more, the protein appears to trigger cancer's spread in part by blocking two other proteins that are normally linked to neurodegeneration, a finding that suggests these two disease processes could have unexpected ties.

The study, which appears in the July 10 issue of Nature, points to the possibility of new cancer therapies that target this "master regulator" that helps set metastasis in motion.

"Although the research is in its very early days, if we learn more about how this regulation works, we may in the future be able to generate drugs that prevent this protein from triggering ," says Sohail F. Tavazoie, senior author on the study. Tavazoie is Leon Hess Assistant Professor and head of the Vincent Meyer Laboratory of Systems Cancer Biology at Rockefeller.

During the study, Tavazoie and his colleagues used technology previously developed by first author Hani Goodarzi and co-author Saeed Tavazoie, a professor at Columbia University, to measure a new layer of regulation in . In order to understand what triggers cells to become malignant, scientists often look at sequences of DNA, searching for genes which are turned on or off in cancerous cells. But in recent years, they've uncovered many new mechanisms that govern cell activity, including some that act on RNA, the genetic material that helps cells make proteins using instructions encoded in DNA. The special strength of Goodarzi and Saeed Tavazoie's tool is that it doesn't look simply at the sequence of RNA–it also looks at its shape.

It turns out, the shape of an RNA molecule matters. Specifically, some segments of messenger RNA form hairpin loops, which create sites for key proteins to bind to and regulate that RNA – telling the cell to destroy it, for instance. "These structural differences help determine RNA's fate, by exposing or hiding the binding sites for those key proteins," says Goodarzi.

So Goodarzi and Saeed Tavazoie developed a computer algorithm that scans samples of cancer cells and identifies patterns in the shapes and sequences of RNA. In the current study, the authors applied this algorithm to . In cells prone to metastasis, for example, the scientists found certain RNA hairpin loops that were overrepresented in the sequences of RNAs targeted for destruction. They then identified a protein that binds to those hairpin sequences – TARBP2, known to play a role in the formation of small RNAs known as microRNAs. But here, it appears TARBP2 can also act as a "master regulator" of RNA itself, by binding to multiple sites and causing a suite of changes that lead to metastasis – including the destruction of the RNAs that carry those key binding sites. Indeed, they found that TARBP2 is overexpressed in cells prone to metastasizing, as well as in metastatic human breast tumors themselves.

To determine how TARBP2 carries out its effects, the researchers looked at which genes appear to be downregulated in metastatic cell lines, reasoning that TARBP2 may block these disease suppressors. They made two surprising discoveries – APP, a protein linked to Alzheimer's disease, and ZNF395, which is associated with Huntington's disease, are both downregulated by TARBP2. Cells prone to metastasis showed higher levels of TARBP2 and lower levels of APP and ZNF395; in cancer cells that tend not to spread throughout the body, the opposite was true.

"This was a surprising finding, because these genes are normally associated with neurodegeneration are now implicated in and progression," says Tavazoie. "It's interesting that these totally disparate disease processes have a potential molecular link. We don't know what that means yet."

In further experiments, they discovered that ZNF395 appears to decrease the expression of genes linked to cancer, while one segment of APP directly inhibits breast cancer's ability to metastasize.

The study raises hopes of new cancer therapies that target this "master regulator," TARBP2. "If we can understand the mechanism by which TARBP2 interacts with RNA, maybe in the future we could generate drugs that prevent it from sitting on RNA structures and shutting down the genes that suppress metastatic disease," says Tavazoie.

Just what these findings say about the relationship between cancer and neurodegeneration – two of the most common diseases of old age – is still unclear, he adds. "All we can say here is that APP and ZNF395, besides being associated with neurodegeneration, also seem to play a functional role in the progression of breast cancer. We can't really make any statements about why this is – it could simply be that cells use whatever mechanisms necessary to spread throughout the body, and these genes serve that purpose."

Of course, any future therapies that halt metastasis by blocking TARBP2 will have to sidestep the potential risk of promoting neurodegeneration in the process, cautions Goodarzi. All of that will have to be worked out in the lab, agrees Tavazoie.

Funding for the research was provided in part by the National Institutes of Health and the Department of Defense.

Explore further: In cancer, molecular signals that recruit blood vessels also trigger metastasis

More information: Metastasis-suppressor transcript destabilization through TARBP2 binding of mRNA hairpinsdx.doi.org/10.1038/nature13466

Related Stories

In cancer, molecular signals that recruit blood vessels also trigger metastasis

December 19, 2011
(Medical Xpress) -- Cancer cells are most deadly when they’re on the move — able not only to destroy whatever organ they are first formed in, but also to create colonies elsewhere in the body. New research has now ...

Stopping the spread of breast cancer

June 3, 2014
The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body. Northwestern Medicine® scientists have discovered a new pathway that can stop breast cancer cells from ...

Drug is identified that could block the spread of melanoma

April 3, 2014
(Medical Xpress)—Cancer is at its most curable when it's caught before it spreads. That's especially true in the case of melanoma, where survival rates can be as high as 97 percent when caught early—and as low as 15 percent ...

Signalling protein plays different roles in breast cancer and normal cells

June 20, 2014
A key step in developing effective cancer therapies is identifying differences between normal, healthy cells and cancer cells – these differences can then be exploited to specifically kill tumour cells.

Team highlights new mechanism explaining how cancer cells spread

May 28, 2014
UT Southwestern Medical Center cancer researchers have identified a protein critical to the spread of deadly cancer cells and determined how it works, paving the way for potential use in diagnosis and eventually possible ...

Researchers reveal treasure trove of genes key to kidney cancer

July 1, 2014
A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.